CN107074922A - 用于糖尿病慢性并发症的socs1衍生肽 - Google Patents

用于糖尿病慢性并发症的socs1衍生肽 Download PDF

Info

Publication number
CN107074922A
CN107074922A CN201580040669.6A CN201580040669A CN107074922A CN 107074922 A CN107074922 A CN 107074922A CN 201580040669 A CN201580040669 A CN 201580040669A CN 107074922 A CN107074922 A CN 107074922A
Authority
CN
China
Prior art keywords
diabetic
sequence
diabetes
polypeptide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580040669.6A
Other languages
English (en)
Chinese (zh)
Inventor
耶稣·艾吉多德洛斯里奥斯
卡门·戈麦斯格雷罗
拉斐尔·斯莫卡南戈
克里斯蒂娜·埃尔南德斯帕斯卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Autonoma de Madrid
Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Original Assignee
Universidad Autonoma de Madrid
Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Autonoma de Madrid, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz, Fundacio Institut de Recerca Hospital Universitari Vall dHebron filed Critical Universidad Autonoma de Madrid
Publication of CN107074922A publication Critical patent/CN107074922A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201580040669.6A 2014-05-28 2015-05-27 用于糖尿病慢性并发症的socs1衍生肽 Pending CN107074922A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201430796 2014-05-28
ES201430796A ES2552587B1 (es) 2014-05-28 2014-05-28 Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes
PCT/ES2015/070415 WO2015181427A1 (es) 2014-05-28 2015-05-27 Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes

Publications (1)

Publication Number Publication Date
CN107074922A true CN107074922A (zh) 2017-08-18

Family

ID=53546661

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580040669.6A Pending CN107074922A (zh) 2014-05-28 2015-05-27 用于糖尿病慢性并发症的socs1衍生肽

Country Status (13)

Country Link
US (2) US10532082B2 (enExample)
EP (1) EP3178485B1 (enExample)
JP (1) JP6681387B2 (enExample)
CN (1) CN107074922A (enExample)
BR (1) BR112016027936A2 (enExample)
CA (1) CA2950348A1 (enExample)
ES (2) ES2552587B1 (enExample)
HU (1) HUE041836T2 (enExample)
MX (1) MX369378B (enExample)
PL (1) PL3178485T3 (enExample)
PT (1) PT3178485T (enExample)
TR (1) TR201903509T4 (enExample)
WO (1) WO2015181427A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552587B1 (es) 2014-05-28 2017-01-18 Fundació Hospital Universitari Vall D'hebron-Institut De Recerca Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes
CN105315377A (zh) * 2015-12-07 2016-02-10 华东理工大学 带有穿膜肽的tcs融合蛋白、质粒及制备方法与应用
EA038338B1 (ru) * 2016-02-23 2021-08-11 Такеда Фармасьютикал Компани Лимитед Ингибиторы взаимодействий -аррестина с рецептором нейрокинина 1 для лечения боли
CN106349347B (zh) * 2016-10-25 2019-09-13 南通大学 一种小分子多肽、及其编码基因和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175971A1 (en) * 2001-12-28 2003-09-18 Geoffrey Lindeman Differentiation and/or proliferation modulating agents and uses therefor
CN101437834A (zh) * 2004-07-19 2009-05-20 贝勒医学院 细胞因子信号转导调节剂的调节和用于免疫治疗的应用
WO2011113048A2 (en) * 2010-03-12 2011-09-15 Vanderbilt University Modulation of cytokine signaling
CN102921007A (zh) * 2011-08-09 2013-02-13 中国科学院上海生命科学研究院 防治胰岛素抵抗和糖尿病的方法和试剂
US8420096B2 (en) * 2004-03-04 2013-04-16 Vanderbilt University Cell-penetrating SOCS polypeptides that inhibit cytokine-induced signaling
CN103173446A (zh) * 2011-12-26 2013-06-26 吕成伟 一种靶向干扰socs1基因的重组腺相关病毒载体的构建方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1849474B1 (en) 2005-02-15 2016-09-07 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
US20090253618A1 (en) 2005-07-20 2009-10-08 Hiroshi Kanno Neuronal differentiation-inducing peptide and use thereof
WO2010151495A2 (en) 2009-06-26 2010-12-29 University Of Florida Research Foundation Inc. Materials and methods for treating and preventing viral infections
ES2552587B1 (es) 2014-05-28 2017-01-18 Fundació Hospital Universitari Vall D'hebron-Institut De Recerca Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175971A1 (en) * 2001-12-28 2003-09-18 Geoffrey Lindeman Differentiation and/or proliferation modulating agents and uses therefor
US8420096B2 (en) * 2004-03-04 2013-04-16 Vanderbilt University Cell-penetrating SOCS polypeptides that inhibit cytokine-induced signaling
CN101437834A (zh) * 2004-07-19 2009-05-20 贝勒医学院 细胞因子信号转导调节剂的调节和用于免疫治疗的应用
WO2011113048A2 (en) * 2010-03-12 2011-09-15 Vanderbilt University Modulation of cytokine signaling
CN102921007A (zh) * 2011-08-09 2013-02-13 中国科学院上海生命科学研究院 防治胰岛素抵抗和糖尿病的方法和试剂
CN103173446A (zh) * 2011-12-26 2013-06-26 吕成伟 一种靶向干扰socs1基因的重组腺相关病毒载体的构建方法与应用

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHENG-RONG YU ET AL.: "Suppressor of cytokine signaling-1（SOCS1） inhibits lymphocyte recruitment into the retina and protects SOCS1 Transgenic Rats and Mice from Ocular Inflammation", 《INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE》 *
GUADALUPE ORTIZ-MUNOZ ET AL.: "Suppressors of Cytokine Signaling Abrogate Diabetic Nephropathy", 《JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY》 *
LINDSEY D. JAGER ET AL.: "The Kinase Inhibitory Region of SOCS-1 is Sufficient to Inhibit T-helper 17 and other Immune Functions in Experimental Allergic Encephalomyelitis", 《JOURNAL OF NEUROIMMUNOLOGY》 *
光敏等: "炎症因子与糖尿病及其血管并发症", 《中华临床医师杂志》 *
兰文等: "糖尿病视网膜病变炎症的研究新进展", 《眼科新进展》 *
刘青娟: "炎症在糖尿病肾病发病中的作用及细胞因子信号转导抑制因子SOCS-1、SOCS-3的影响", 《中国博士学位论文全文数据库 医药卫生科技辑》 *
崔强等: "一种新的疾病治疗候选基因：SOCS-1", 《生命科学》 *
徐晓鹤等: "炎症反应及细胞因子与糖尿病视网膜病变", 《国际眼科杂志》 *
邓尚平等: "《糖尿病防治知识讲座》", 30 April 2007, 四川科学技术出版社 *

Also Published As

Publication number Publication date
MX369378B (es) 2019-11-07
PL3178485T3 (pl) 2019-07-31
MX2016015514A (es) 2017-05-04
EP3178485B1 (en) 2018-12-12
US20170209536A1 (en) 2017-07-27
JP2017524727A (ja) 2017-08-31
BR112016027936A2 (pt) 2017-10-24
WO2015181427A1 (es) 2015-12-03
US20200138903A1 (en) 2020-05-07
ES2552587A2 (es) 2015-11-30
HUE041836T2 (hu) 2019-05-28
JP6681387B2 (ja) 2020-04-15
PT3178485T (pt) 2019-03-22
EP3178485A1 (en) 2017-06-14
US10532082B2 (en) 2020-01-14
ES2552587B1 (es) 2017-01-18
TR201903509T4 (tr) 2019-04-22
ES2552587R1 (es) 2016-02-10
ES2715412T3 (es) 2019-06-04
CA2950348A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
Wu et al. Astrocytic YAP protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model through TGF-β signaling
Sun et al. Modulation of the astrocyte-neuron lactate shuttle system contributes to neuroprotective action of fibroblast growth factor 21
Song et al. Application and mechanism of anti-VEGF drugs in age-related macular degeneration
Du et al. A novel role of kallikrein-related peptidase 8 in the pathogenesis of diabetic cardiac fibrosis
US20200138903A1 (en) Socs1-derived peptide for use in chronic complications of diabetes
Xiaohong et al. CFLAR is a critical regulator of cerebral ischaemia-reperfusion injury through regulating inflammation and endoplasmic reticulum (ER) stress
JP2022509445A (ja) 線維症を治療又は予防するための組成物及び方法
Shi et al. Angiotensin II as a morphogenic cytokine stimulating fibrogenesis of human tenon's capsule fibroblasts
KR102379006B1 (ko) 망막 염증 치료에 사용하기 위한 작용제
Tanaka et al. Adrenomedullin–Receptor Activity-Modifying Protein 2 System Ameliorates Subretinal Fibrosis by Suppressing Epithelial-Mesenchymal Transition in Age-Related Macular Degeneration
Gao et al. Lack of elevated expression of TGFβ3 contributes to the delay of epithelial wound healing in diabetic corneas
EP2152292A1 (en) Angiogenesis inhibitor comprising meteorin as an active ingredient
US20220211810A1 (en) Method of Treatment
Deng et al. The effect of dietary vitamin K1 supplementation on trabecular meshwork and retina in a chronic ocular hypertensive rat model
Yamamoto et al. Phosphorylation of αB-Crystallin Involves Interleukin-1β-Mediated Intracellular Retention in Retinal Müller Cells: A New Mechanism Underlying Fibrovascular Membrane Formation
Kucuk et al. Therapeutic potential of erythropoietin in retinal and optic nerve diseases
Zhong et al. SUMOylation is a Translatable Target in Hypoxic MNPs Regulating Retinal Vasculopathy
WO2025083211A1 (en) Use of factor h for the treatment of dementia
Lu et al. Anti-fibrosis effect of nanoparticle-mediated delivery of plasminogen kringle 5
WO2017115059A1 (fr) Fragment du facteur h pour son utilisation comme agent anti-angiogénique
Márquez Regulation of dystrophin Dp71 during Müller glial cells edema in mouse retina
CN116585460A (zh) α1-抗胰蛋白酶与内源性大麻素受体2在药物中的应用
KR20140046781A (ko) 보체인자 ｈ를 포함하는 맥락막 신생혈관 생성 예방 또는 치료용 조성물
CN106102766A (zh) 用于治疗视网膜炎症的试剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170818